Abstract Number: 2959 • 2016 ACR/ARHP Annual Meeting
Baseline Endothelial Dysfunction Might Predict Immunosuppressive Need in Young, Male Behcet’s Patients with Early Disease: A Prospective Follow-up
Background/Purpose: Major organ involvement, especially in young males, is one of the main causes of mortality and morbidity in Behcet’s Disease (BD). However, the prognosis…Abstract Number: 2960 • 2016 ACR/ARHP Annual Meeting
Increased Post-Thrombotic Syndrome Is Unassociated with Anticoagulant Use in Vascular Behcet’s Disease
Background/Purpose: Deep venous thrombosis (DVT) is the most common form of vascular involvement in Behcet’s disease (BD). Chronic post-thrombotic syndrome (PTS) develops frequently in patients…Abstract Number: 2961 • 2016 ACR/ARHP Annual Meeting
Antiphospoholipid Antibodies in Adult IgA Vasculitis: Aps/PT Antibodies As a Potential Marker of Renal Involvement?
Background/Purpose: Increased prevalence of IgA aCL and anti-PS/PT antibodies has been described in adult IgAV, making them potential markers of disease activity1. The aim of our…Abstract Number: 2962 • 2016 ACR/ARHP Annual Meeting
Expression Profile of Chemokines Is Skewed to Th17/Th22 Recruitment in Circulation of Patients with Behcet’s Disease
Background/Purpose: Behcet’s disease (BD) is an inflammatory disease characterized by ocular, mucosal and skin lesions. However, the pathogenesis of BD is still unknown. Characteristics of…Abstract Number: 2963 • 2016 ACR/ARHP Annual Meeting
BehçEt’s Disease in Children: Eastern Mediterranean Experience
Background/Purpose: Behçet’s disease (BD) is a variable vessel vasculitis which is more common in adults. The most widely used diagnostic criteria for adult onset disease…Abstract Number: 2964 • 2016 ACR/ARHP Annual Meeting
Thromboangiitis Obliterans (Buerger’s disease) : An Observational Study of 174 Patients
Background/Purpose: Buerger’s disease or thromboangiitis obliterans (TAO) is a nonatherosclerotic segmental inflammatory disease of small- and medium-sized arteries of the distal extremities. This disease mainly…Abstract Number: 2965 • 2016 ACR/ARHP Annual Meeting
Late-Onset Relapse in Patients with Systemic Vasculitis
Background/Purpose: Little is known about the incidence of late-onset relapse in systemic vasculitis. This study examined the incidence of relapse < 2 years and ≥ 2…Abstract Number: 2966 • 2016 ACR/ARHP Annual Meeting
Assessment of Damage in Behcet’s Disease: Do We Need a Specific Damage Index?
Background/Purpose: Behcet’s Disease (BD) is a systemic vasculitis characterized by involvement of vessels of any size and type. In the course systemic vasculitis, it is…Abstract Number: 2967 • 2016 ACR/ARHP Annual Meeting
Identifying Core Domains for BehçEt’s Syndrome Trials: An International Physician and Patient Delphi Exercise
Background/Purpose: An unmet need for reliable, validated, and widely accepted outcome measures for trials in BehetÕs syndrome (BS) was identified through: i) a systematic review;…Abstract Number: 2968 • 2016 ACR/ARHP Annual Meeting
Efficacy of Anti-TNF Alpha in Severe and Refractory Cardiovascular Involvement of Behcet’s Disease: A Multicenter Observational Study of 18 Patients
Background/Purpose: In Behçet's disease (BD), vascular complications affect more than 30% patients. Cardiovascular involvement is the main cause of death, especially for pulmonary or aortic…Abstract Number: 2969 • 2016 ACR/ARHP Annual Meeting
10 Year Retrospective Analysis of 276 Cases of Histopathologically Confirmed Leukocytoclastic Vasculitis
Background/Purpose: We identified leukocytoclastic vasculitis (LCV) patients seen over 10 years at our institution. Aims included 1) define cause; 2) record lab, imaging, and ancillary…Abstract Number: 2970 • 2016 ACR/ARHP Annual Meeting
Incidence and Characteristics of Vasculitis Associated with Monoclonal Antibodies and Peptide Fusion Proteins: A Survey from the French National Pharmacovigilance Database
Background/Purpose: Immunological classes of adverse events (AEs), including the immune related AEs and the paradoxical effects, have emerged with the used of biologics. Among them,…Abstract Number: 2971 • 2016 ACR/ARHP Annual Meeting
Characteristics and Management of IgA Vasculitis (Henoch-Schönlein purpura) in Adults: Data from the 260 Patients Included in the Igavas Survey
Background/Purpose: We analyzed data from 260 patients with IgAV included in a French multicenter retrospective IGAVAS survey. Results: Mean age at diagnosis was 50.1±18 years,…Abstract Number: 2972 • 2016 ACR/ARHP Annual Meeting
Vaccination and Risk of Childhood IgA Vasculitis (Henoch–Schönlein): A Case-Crossover Analysis
Background/Purpose: The etiology of IgA vasculitis (Henoch–Schönlein, IgAV), the most common systemic vasculitis in children, is unknown, although seasonality in disease onset and clinical observation…Abstract Number: 2973 • 2016 ACR/ARHP Annual Meeting
A Comparison of Caregiving Burden and Impact in Systemic Vasculitis Versus Other Conditions
Background/Purpose: Serving as an informal caregiver to a family member or friend with a chronic illness is associated with stress, reduced health status, and financial…
ACR Meeting Abstracts